Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

EpCAM (CD326) finding its role in cancer.

Baeuerle PA, Gires O.

Br J Cancer. 2007 Feb 12;96(3):417-23. Epub 2007 Jan 9. Review. Erratum in: Br J Cancer. 2007 May 7;96(9):1491.

2.

Role of the EpCAM (CD326) in prostate cancer metastasis and progression.

Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, Li Y.

Cancer Metastasis Rev. 2012 Dec;31(3-4):779-91. doi: 10.1007/s10555-012-9389-1. Review.

PMID:
22718399
3.

Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.

Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC.

Am J Pathol. 2007 Aug;171(2):386-95. Epub 2007 Jun 28. Review.

4.

Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.

Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA.

Clin Cancer Res. 2004 Apr 15;10(8):2659-69.

5.

EpCAM in carcinogenesis: the good, the bad or the ugly.

van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG.

Carcinogenesis. 2010 Nov;31(11):1913-21. doi: 10.1093/carcin/bgq187. Epub 2010 Sep 13. Review.

PMID:
20837599
6.

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.

Patriarca C, Macchi RM, Marschner AK, Mellstedt H.

Cancer Treat Rev. 2012 Feb;38(1):68-75. doi: 10.1016/j.ctrv.2011.04.002. Epub 2011 May 14. Review.

PMID:
21576002
7.

The emerging role of EpCAM in cancer and stem cell signaling.

Munz M, Baeuerle PA, Gires O.

Cancer Res. 2009 Jul 15;69(14):5627-9. doi: 10.1158/0008-5472.CAN-09-0654. Epub 2009 Jul 7. Review.

8.

The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP.

Münz M, Zeidler R, Gires O.

Cancer Lett. 2005 Jul 8;225(1):151-7. Epub 2004 Dec 28.

PMID:
15922867
9.

Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines.

Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, Fukushima K, Shiina M, Yamagiwa Y, Kondo Y, Inoue J, Kakazu E, Iwasaki T, Kawagishi N, Shimosegawa T, Sugamura K.

Cancer Sci. 2010 Oct;101(10):2145-55. doi: 10.1111/j.1349-7006.2010.01661.x. Epub 2010 Aug 12.

10.

Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer.

van der Gun BT, Huisman C, Stolzenburg S, Kazemier HG, Ruiters MH, Blancafort P, Rots MG.

Br J Cancer. 2013 Mar 5;108(4):881-6. doi: 10.1038/bjc.2013.45. Epub 2013 Feb 12.

11.

EpCAM proteolysis: new fragments with distinct functions?

Schnell U, Kuipers J, Giepmans BN.

Biosci Rep. 2013 Mar 19;33(2):e00030. doi: 10.1042/BSR20120128.

12.

Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells.

Hase T, Sato M, Yoshida K, Girard L, Takeyama Y, Horio M, Elshazley M, Oguri T, Sekido Y, Shames DS, Gazdar AF, Minna JD, Kondo M, Hasegawa Y.

Cancer Sci. 2011 Aug;102(8):1493-500. doi: 10.1111/j.1349-7006.2011.01973.x. Epub 2011 Jun 2.

13.

Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.

Yamashita T, Budhu A, Forgues M, Wang XW.

Cancer Res. 2007 Nov 15;67(22):10831-9.

14.

Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.

Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD, Sondel P.

J Immunother. 2004 May-Jun;27(3):211-9.

PMID:
15076138
15.

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.

Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H.

Br J Cancer. 2007 Aug 6;97(3):315-21. Epub 2007 Jul 10.

16.

EpCAM in morphogenesis.

Trzpis M, Bremer E, McLaughlin PM, de Leij LF, Harmsen MC.

Front Biosci. 2008 May 1;13:5050-5. Review.

PMID:
18508569
17.
18.

Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas.

Pauli C, Münz M, Kieu C, Mack B, Breinl P, Wollenberg B, Lang S, Zeidler R, Gires O.

Cancer Lett. 2003 Apr 10;193(1):25-32.

PMID:
12691820
19.

EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.

Hristodorov D, Amoury M, Mladenov R, Niesen J, Arens K, Berges N, Hein L, Di Fiore S, Pham AT, Huhn M, Helfrich W, Fischer R, Thepen T, Barth S.

Mol Cancer Ther. 2014 Sep;13(9):2194-202. doi: 10.1158/1535-7163.MCT-13-0781. Epub 2014 Jun 30.

20.

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA.

Br J Cancer. 2006 Jan 16;94(1):128-35.

Supplemental Content

Support Center